Kornimate/medical-research-clean huggingface dataset:
effect of tramadol versus morphine on pd1 and pd1-ligand in patients with chronic cancer pain

Conditions: Chronic Pain

Summary: this work is looking for comparison between the effect of tramadol versus morphine on pd1 and pd1-ligand in patients with chronic cancer pain

the use of opioids is the mainstay in the treatment of many types of chronic pain, including cancer and non-cancer-related pain\]. opioids are known to suppress immune function following both acute and chronic administration; however, they appear to be different according to the schedule of administration as well as the state of the organism. programmed death-1 (pd-1, also known as cd279) belongs to the cd28 receptor superfamily. it is an inhibitory receptor, and its expression is upregulated on activated leukocytes, resulting in an inhibited immune response. pd-1 interacts with two ligands: programmed death ligand-1 (pd-l1, also referred to as b7-h1) and programmed death ligand-2 (pd-l2, also known as b7-dc). pd-l2 is expressed mainly on activated dendritic cells (dcs) and macrophages, whereas pd-l1 is distributed widely. in addition to immune cells, some subsets of tumor cells also express pd-l1 to escape from immunosurveillance. it has been reported that the pd-1/pd-l1 pathway could be activated by surgical stress.

Eligibility criteria:
inclusion criteria: * patients with cancer pain of varying etiology, * documented metastatic cancer, currently on step i who ladder and whose pain necessitates a shift to step ii, * those who have never received radiotherapy, chemotherapy, or immunosuppressive drugs, -- and in good general and nutritional condition and without infectious diseases at the time of investigation. exclusion criteria: * abnormal hepatic, renal, and pulmonary function, gastrointestinal pathology, and * those with cerebral metastases and/or psychological disorders, * patients with contraindication to morphine or tramadol according to their respective data sheets, and * patients who could not complete the diary information correctly.

Keywords: morphine tramadol pd1 and pd1 ligand
health-related symptom questionnaires in measuring quality of life in hiv-infected participants treated or monitored for anal lesions

Conditions: High Grade Anal Canal Squamous Intraepithelial Neoplasia; HIV Infection

Summary: this research trial studies health-related symptom questionnaires in measuring quality of life in human immunodeficiency virus (hiv)-infected participants treated with or monitored for anal lesions. collecting information and symptoms from patients diagnosed with anal lesions may help reduce the risk of anal cancer.

primary objectives: i. to develop an anal cancer/hsil outcomes research study (anchor) high-grade squamous intraepithelial lesion (hsil) health-related quality of life (hrqol) index (hqi) using state-of-the-art measure development methodology that captures the most important hrqol symptoms and concerns of those persons diagnosed with anal hsil and either treated or untreated for anal hsil. outline: participants complete the anchor hsil hrqol interview over 45-60 minutes, comparing the list of symptoms, concerns, or hrqol impacts related to hsil diagnosis and treatment. some patients also complete a cognitive interview for up to 3 sessions.

Eligibility criteria:
inclusion criteria: * hiv-1 infection * biopsy-proven anal hsil within the prior six months * life expectancy of greater than 5 years exclusion criteria: * history of anal cancer * inability to understand a written consent form
water versus land based perturbation exercises in elderly participants with back pain

Conditions: Back Pain; Back Pain With Radiation; Back Pain Without Radiation; Back Pain Lower Back Chronic

Summary: the aim of this study was to compare the effectiveness of land based versus water based perturbation exercises on the pain, disability, fear of falling, and fear avoidance beliefs in elderly participants. overweight/obese subgroup was compared with healthy weight with chronic low back pain participants to investigate any effect on bmi on both interventions. the results of the study revealed that both exercise groups i.e., land and water based exercise had a significant reduction in pain level, fear of falling, fear avoidance belief related to work, disability and improved slr.

twenty-four grouped into 12 per group participated water based and land based exercise protocol. both groups were given mckenzie method of exercises in 1st week based on the treatment-based classification (tbc) approach or personalized to the need of participants as per tbc. perturbation-based postural exercises were given to participants, which were performed on land or water for 6 weeks. the perturbation based exercises were categorized into four levels, where level 1:static postural control, 2:dynamic postural control 3:extremity loaded postural control and 4: cognitive task associated postural control. the perturbation were provided at shoulder and hip level, by intervention providers progressive enough to initiate anticipatory or compensatory postural adjustments. both groups were educated on pain assurance and spinal ergonomics feedback. the outcomes were measured using a visual analog scale, oswestry disability index, fear avoidance belief questionnaire, straight leg raise, modified fall efficacy scale, and borg scale. the pain level were assessed for personalized progression from level 1 to level 4 progression of perturbation exercises. both the exercise groups of land and water showed improvement in measured clinical outcomes in terms of reduction in pain level, fear of falling, fear avoidance belief related to work, slr, and disability. water-based group showed additional benefits and significant improvement in fear avoidance belief related to physical activity and exercised with low rate of perceived exertion.

Eligibility criteria:
inclusion criteria: * pain history of minimum 12 weeks duration in below labels * participants with the diagnostic labels of spondylosis * non-specific chronic low back pain * back pain radiating to leg or sciatica * subacute back pain exclusion criteria: * unstable blood pressure * cardiac failure * incontinence * uncontrolled epilepsy * open wounds * acute infections * neurological disorders * orthopedic conditions affecting exercise participation in pool and land * cardio-respiratory conditions affecting exercise participation in pool and land.

Keywords: back pain old age exercises hydrotherapy rehabilitation
inspiratory muscle training in chronic thromboembolic pulmonary hypertension

Conditions: Chronic Thromboembolic Pulmonary Hypertension; Inspiratory Muscle Training; Inspiratory Muscle Weakness

Summary: inspiratory muscle training for 8 weeks in patients with chronic thromboembolic pulmonary hypertension.

32 patients with cteph (confirmed by right cardiac catheterization and imaging) will perform: 1) pulmonary function tests; 2) measurement of maximal inspiratory pressure (mip) and endurance; 3) evaluation of peripheral muscle strength by isokinetic dynamometry; 4) six-minute walk test and 5) incremental and constant load cardiopulmonary exercise test (\~ 75% of maximal work-rate) with non-invasive evaluation of central hemodynamics and peripheral muscle oxygenation. inspiratory muscle training will consist of twice daily sessions of 30 breaths (\~ 50% pimax, 4-5 minutes per session) for 8 weeks. the sham group will perform sessions of 30 breaths with no inspiratory load.

Eligibility criteria:
inclusion criteria: * cteph confirmed by rhc and imaging * nyha fc ii-iv exclusion criteria: * limitation to cycling * recent syncope or clinical deterioration
effectiveness of meshed free gingival graft for widening of keratinized tissues

Conditions: Gingiva Atrophy

Summary: the overall objective of this project is to evaluate, over a period of 1 year, the outcomes of either conventional free gingival graft (fgg) or mesh-fgg to increase the width of keratinized mucosa (km) at implant sites.

the importance of the width of keratinized mucosa (km) at implant sites remains a subject of ongoing debate. reduced dimensions of km (width \<2 mm) are associated with mucosal recession, biofilm accumulation, soft-tissue inflammation, marginal bone loss, peri-implantitis and patient discomfort. surgical options to increase the width of km include an apically positioned flap, either alone or in combination with an autogenous graft or a xenogeneic collagen matrix. the free gingival graft (fgg) is a well-established technique with a history of successful clinical use. the harvesting procedure for autogenous graft from the palatal mucosa, however, is usually associated with significant patient morbidity, especially when there is a need to graft extensive mucosal areas. to overcome this problem, various graft modifications have been proposed to limit the need for large-area autografts. examples include the accordion technique, the strip gingival autograft technique, and a vertical modification of the strip gingival graft. the expanded mesh graft, another graft modification, has been used in the field of plastic surgery, especially in the treatment of large burn wounds. recently, de greef, carcuac, de mars et al. proposed this technique to be used in periodontal plastic surgery, more specifically, in the widening of km at implant sites by means of a meshed free gingival graft (mesh-fgg). in this case series, initially inadequate width of km in edentulous areas could be successfully increased prior to implant installation, without the need for any extensive autograft harvesting. data from trials comparing mesh-fgg to conventional fgg and assessing the long-term efficacy of this novel technique, however, are missing. the investigators hypothesize that the mesh-fgg technique will demonstrate similar clinical results (non-inferiority: increase in km width) but improved patient-reported outcomes (superiority: post-surgical morbidity) compared to the fgg.

Eligibility criteria:
inclusion criteria: * ≥18 years of age, * systemically healthy, * presence of ≥2 adjacent implants in both sides of the mandibles showing \<2 mm of km on the buccal aspects, * subjects have to present with discomfort from brushing and/or difficulties in maintaining proper home care due to inadequate dimension of km * full-mouth plaque score (fmps) \<20%, * full-mouth bleeding score (fmbs) \<20%. exclusion criteria: * pregnancy or lactation, * tobacco smoking, * uncontrolled medical condition, * medication that can affect gingival conditions.
mindfulness and yoga therapy for acute pain in sickle cell disease

Conditions: Sickle Cell Crisis; Sickle Cell Disease

Summary: patients with sickle cell disease suffer from acute and chronic pain that diminishes their quality of life. the purpose of this study is to assess the feasibility and acceptability of mindfulness meditation, breathing exercises, and gentle yoga therapy as supportive measures for the management of acute vaso-occlusive pain crises in the inpatient setting.

this is a prospective single arm study of mindfulness interventions for sickle cell patients admitted with an acute vaso-occlusive pain crisis. patients will be accrued over a consecutive 12 week period. all genotypes of sickle cell disease will be eligible for enrollment. after providing informed consent, the patients will have access to 4 videos on their hospital room television. the videos contain guided mindfulness meditation, breathing exercises (including the use of an incentive spirometer), and gentle yoga therapy that can be performed in the supine position from a hospital bed. videos vary in length from 5-12 minutes. participants will have the ability to watch the videos as many times as they choose. they may also turn off the video at any time. the primary outcome is feasibility and acceptability of the intervention. we will record objective data on how many videos are watched by each participant, as well as the percentage of each video completed. we will obtain information about the participants' perception of the intervention through a post-intervention survey and interview.

Eligibility criteria:
inclusion criteria: * patients with sickle cell disease, any genotype * adult patients at least 18 years of age * english speaking * admitted to clements university hospital with an acute vaso-occlusive pain crisis exclusion criteria: * unable to follow simple instructions * admitted to the intensive care unit

Keywords: sickle cell disease yoga therapy mindfulness
a global phase 3 study of orelabrutinib+br vs.br in pts with tn mcl

Conditions: Mantle Cell Lymphoma

Summary: compare the efficacy and safety of orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (mcl)


Eligibility criteria:
inclusion criteria: 1. subjects ≥ 65 of age, or ≥ 60 and \< 65 years old who are ineligible for stem cell transplant or have refused stem cell transplantation due to reason(s) including: have not received prior systemic therapies for mcl. 2. modified ann arbor stage ii-iv. patients with stage ii require systemic treatment to be eligible, at the discretion of the investigator. 3. histopathological confirmed mcl, expression of cyclin d1 and/or t (11; 14) chromosomal translocation. either fresh tissue or ffpe for diagnosis must be sent to central lab for final confirmation after randomization. 4. at least one measurable site of disease (the longest axis of the lymph node lesion is \> 1.5 cm, or the longest diameter of the extranodal lesion is \> 1.0 cm). 5. ecog ps score of 0 to 2. exclusion criteria: 1. existing or prior history of other malignant tumor and no evidence of recurrence and metastasis within 2 years before screening. 2. subjects with evident gastrointestinal dysfunction that may affect drug intake, transport or absorption, or subjects who have undergone total gastrectomy. 3. subjects for whom the goal of therapy is tumor debulking prior to stem cell transplant. 4. use of strong inhibitors or strong inducers of cytochrome p450 3a within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment; or plan to use strong inhibitors or strong inducers of cyp3a during the study. 5. known central nervous system lymphoma.
efficacy and safety study of catheter ablation for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: to compare the efficacy of different procedures, identify the optimal procedure, ablation sites, ablation endpoints and post-operative anticoagulation strategy, establish the optimal treatment strategy for atrial fibrillation.


Eligibility criteria:
inclusion criteria: 1. atrial fibrillation recorded by ecg or holter; 2. age: 18 \~ 75 years; 3. patients who are willing to enroll in the trial exclusion criteria: 1. patients accompanied hyperthyroidism; 2. patients with sever liver or renal dysfunction; 3. patients with sever cardiac dysfunction; 4. patients had previous radiofrequency catheter ablation in the la or maze surgical procedure; 5. patients with emboli in atrium; 6. pregnant woman
efficacy of blastx in catheter associated bacteriuria versus standard of care (soc)

Conditions: Urinary Tract Infections

Summary: this is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. subjects will be randomized 1:1 to either the biofilm disrupting gel (blastx) or soc (mckesson jelly) lubricated catheters. urine and/or catheter dna analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

this is a 2-week, single-site, randomized controlled pilot study in adults requiring short-term \< 14 days catheterization. subjects will be randomized 1:1 to either the blastx or soc lubricated catheters. urine and catheter dna analysis will be obtained at catheter insertion, 2 to 3 days after catheterization and at 5, 7 and 14 days if catheterization was indicated for either duration. informed consent discussion will be completed, icf will be signed, prior to any study procedures. subjects will be included only if all of the inclusion criteria and none of the exclusion criteria have been met. after randomization, subjects will be followed, urine samples will be collected at each scheduled visit and the catheters will be collected upon removal.

Eligibility criteria:
inclusion criteria: 1. 18 years or older 2. absence of symptomatic uti 3. absence of upper/lower tract obstructions 4. no known allergies to the study products 5. willing to comply with all study procedures and available for the duration of the study exclusion criteria: 1. 17 years or younger 2. symptomatic uti 3. presence of upper/lower tract obstructions 4. known allergic reaction to the study products 5. unable to provide signed and dated informed consent form

Keywords: foley, uti, biofilm, dna
washed microbiota transplantation combined with enteral nutrition for gastroptosis

Conditions: Gastroptosis; Malnutrition

Summary: this is a observational study to explore the efficacy and safety of washed microbiota transplantation (wmt) combined with nutritional support for gastroptosis patients


Eligibility criteria:
inclusion criteria: * subjects must meet all of the following inclusion criteria to enter the study: 1. clinically diagnosed with gastroptosis; 2. meets the diagnostic criteria for malnutrition (fulfilling any one of the following two criteria): * weight loss (weight loss \>5% within the last 6 months or \>10% over more than 6 months); * low bmi (bmi \<18.5 kg/m² for individuals \<70 years old; bmi \<20 kg/m² for individuals ≥70 years old); 3. males aged ≥18 years and non-pregnant, non-lactating females aged ≥18 years; 4. willing to voluntarily sign a written informed consent form and agrees to follow medical advice for regular follow-up examinations and monitoring after the completion of treatment. exclusion criteria: * subjects meeting any of the following exclusion criteria must be excluded from the study: 1. patients with severe depression, anxiety, or cognitive impairment that affects normal physician-patient communication and treatment planning; 2. patients with poor compliance who cannot accept treatment regimens such as nasogastric enteral nutrition; 3. anticipated survival time \<3 months; 4. clinically significant cardiovascular diseases, including heart failure (nyha class iii-iv), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, history of myocardial infarction, hemodynamic instability at enrollment, unstable vital signs, or anticipated risk events during treatment; 5. poor pulmonary function deemed by investigators to impact study treatment (e.g., acute exacerbation of copd or requirement for long-term oral/intravenous corticosteroids \[excluding inhaled corticosteroids\]); 6. active severe clinical infections (\> grade 2 per nci-ctcae v5.0), including patients with intestinal fungal, viral, or tuberculosis infections; 7. inability to cooperate with intestinal tube placement or contraindications to intestinal tube placement; 8. use of medications affecting or modulating gut microbiota within the past 48 hours; 9. lack of legal capacity or restricted legal capacity; 10. hematologic disorders unsuitable for blood draw examinations; 11. other severe medical conditions deemed by investigators to preclude patient enrollment.

Keywords: washed microbiota transplantation microbiota medicine gastroptosis malnutrition enteral nutrition transendoscopic enteral tubing
diagnosis and treatment strategy of recurrent spontaneous abortion associated with thrombophilla

Conditions: Thrombophilia With Recurrent Pregnancy Loss

Summary: in this clinical cohort study, the investigators observe the efficacy of low molecular weight heparin in the treatment of thrombophilia with recurrent pregnancy loss with a prospective randomized controlled trial.


Eligibility criteria:
inclusion criteria: * woman who had their second miscarriage before 12(th) week of gestation.the patient who is diagnosed as thrombophilia with recurrent pregnancy loss. signed consent form. exclusion criteria: 1. having experiencedsevere allergies, trauma history and/or operation history within 3 months 2. with a history of mental illness and/or family history of mental illness 3. limb disabled 4. taking medicine within one month 5. suffering major events or having mood swings 6. with a history of recurrent pregnancy loss 7. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine rotine) 8. chromosome aberrations in anyone of the couple. 9. patients who have drug contraindications
assess the effectiveness of atomoxetine in children with fetal alcohol syndrome and add/adhd

Conditions: Fetal Alcohol Syndrome; Attention Deficit Disorder With Hyperactivity (ADHD); Attention Deficit Disorder (ADD)

Summary: the purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.

abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. previous psychological studies have examined either core attention deficit hyperactivity disorder (adhd)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (fas) and adhd. atomoxetine hydrochloride is a non-stimulant medication used to treat adhd. this study will determine if atomoxetine hcl significantly reduces symptoms of add/adhd in children with fetal alcohol exposure.

Eligibility criteria:
inclusion criteria: * patient must be between the ages of 4 and 11 years at the time of entry into the study. * patients must meet diagnostic criteria for fasd * patient must meet dsm-iv criteria for adhd, any subtype and must have an adhdrs-iv score of \> or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age. * patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2. * history and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study. * patients must be able to swallow capsules. * patients must be of a sufficient developmental level (\~3 yrs) to participate in the study. * patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection. * teacher must agree to cooperate with the study. children less than 6 years old must have completed a course of pcit and still meet dsm-iv criteria for adhd. exclusion criteria: * have received an in investigational medication in the past 30 days. * are currently on a medication treatment that is effective (adhdrs-iv score within 1 sd of average) and well tolerated. * have significant current medical conditions that could be exacerbated or compromised by atomoxetine. * have used maois within one month prior to visit 2. * patients with hypertension. * patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder. * patients taking anticonvulsants for seizure control. * patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2. * patients with tourette disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring. * pubertal girls.

Keywords: attention deficit hyperactivity disorder adhd fetal alcohol syndrome fas fasd atomoxetine hcl